Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
…, RJ O'Connell, S Vasan, A Pitisuthitham, Y Sabmee… - The lancet HIV, 2020 - thelancet.com
Background The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521)
and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in …
and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in …
[HTML][HTML] Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised …
…, I Mena, M Meseck, B Phonrat, Y Sabmee… - …, 2022 - thelancet.com
Background Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low-
and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based …
and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based …
[HTML][HTML] Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen …
…, C Sirivichayakul, A Pitisuthitham, Y Sabmee… - …, 2021 - thelancet.com
Background Recombinant pertussis vaccines inducing long-lasting immune responses could
help to control the rise in pertussis. We here report on persisting antibody responses 2 and …
help to control the rise in pertussis. We here report on persisting antibody responses 2 and …
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a …
…, K Boonnak, K Lapphra, Y Sabmee… - The Lancet Infectious …, 2018 - thelancet.com
Background The immunogenicity of acellular pertussis vaccines and persistence of immunity
after vaccination might be improved by using genetically inactivated pertussis toxin (PTgen) …
after vaccination might be improved by using genetically inactivated pertussis toxin (PTgen) …
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2 …
…, K Boonnak, K Lapphra, Y Sabmee… - The Lancet Infectious …, 2018 - thelancet.com
Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We …
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We …
Issues in women's participation in a phase III community HIV vaccine trial in Thailand
…, P Thongcharoen, R Pawarana, Y Sabmee… - AIDS Research and …, 2013 - liebertpub.com
To assess qualities and outcomes of women participating in a large, community-based HIV
vaccine trial, the present study was conducted among female participants of the RV 144 prime…
vaccine trial, the present study was conducted among female participants of the RV 144 prime…
Expectation of volunteers towards the vaccine efficacy of the prime-boost HIV vaccine phase III trial during unblinding
K Khowsroy, J Dhitavat, Y Sabmee… - AIDS Research and …, 2014 - liebertpub.com
A Phase III community-based HIV vaccine trial using the ALVAC-HIV and AIDSVAX B/E
prime-boost regimen (RV144) showed a modest vaccine efficacy of 31.2% against HIV …
prime-boost regimen (RV144) showed a modest vaccine efficacy of 31.2% against HIV …
[PDF][PDF] A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a …
W Phongsamart, K Boonnak, K Lapphra, Y Sabmee… - 2017 - bionet-asia.com
Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We …
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease. We …
[HTML][HTML] Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand
TA Crowell, S Nitayaphan, N Sirisopana… - AIDS Research and …, 2022 - Springer
Background Routine screening for HIV and other sexually transmitted infections (STIs) facilitates
early diagnosis and treatment, thereby preventing morbidity and onward transmission. …
early diagnosis and treatment, thereby preventing morbidity and onward transmission. …
Late Boosting of the RV144 Regimen Improves the Magnitude and Quality of Immune Responses
P Pitisuttithum, S Nitayapha, S Chariyalertsak… - 2019 - papers.ssrn.com
Background: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521)
and AIDSVAX® B/E administration over six months resulted in a 31% efficacy in …
and AIDSVAX® B/E administration over six months resulted in a 31% efficacy in …